{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:51:56Z","timestamp":1791679916776,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100031723","name":"Amgen GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031723","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40744-024-00735-5","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T14:51:45Z","timestamp":1736347905000},"page":"237-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-World Prevalence, Incidence and Management of\u00a0Systemic Lupus Erythematosus in Germany: A\u00a0Retrospective Claims Data Analysis"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-0097","authenticated-orcid":false,"given":"Tobias","family":"Alexander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Sewerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Borchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarcyane Barata","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Schrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"735_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","volume":"80","author":"A Fanouriakis","year":"2021","unstructured":"Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update \u03bfn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80:14.","journal-title":"Ann Rheum Dis"},{"key":"735_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102615","volume":"119","author":"A Thanou","year":"2021","unstructured":"Thanou A, Jupe E, Purushothaman M, Niewold TB, Munroe ME. Clinical disease activity and flare in SLE: current concepts and novel biomarkers. J Autoimmun. 2021;119:102615.","journal-title":"J Autoimmun"},{"key":"735_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s12016-009-8192-4","volume":"40","author":"CE Weckerle","year":"2011","unstructured":"Weckerle CE, Niewold TB. The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol. 2011;40:42\u20139.","journal-title":"Clin Rev Allergy Immunol"},{"key":"735_CR4","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1191\/0961203303lu469xx","volume":"12","author":"P L\u00f3pez","year":"2003","unstructured":"L\u00f3pez P, Mozo L, Guti\u00e9rrez C, Su\u00e1rez A. Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features. Lupus. 2003;12:860\u20135.","journal-title":"Lupus"},{"key":"735_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","volume":"17","author":"MRW Barber","year":"2021","unstructured":"Barber MRW, Drenkard C, Falasinnu T, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17:515\u201332.","journal-title":"Nat Rev Rheumatol"},{"key":"735_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard-2022-223035","volume":"82","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82:351\u20136.","journal-title":"Ann Rheum Dis"},{"key":"735_CR7","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1136\/ard.2010.135186","volume":"69","author":"GK Bertsias","year":"2010","unstructured":"Bertsias GK, Salmon JE, Boumpas DT. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis. 2010;69:1603.","journal-title":"Ann Rheum Dis"},{"issue":"73","key":"735_CR8","first-page":"S116","volume":"30","author":"G Turchetti","year":"2012","unstructured":"Turchetti G, Yazdany J, Palla I, Yelin E, Mosca M. Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider. Clin Exp Rheumatol. 2012;30(73):S116\u201322.","journal-title":"Clin Exp Rheumatol"},{"key":"735_CR9","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1093\/ndt\/gfs073","volume":"27","author":"DYH Yap","year":"2012","unstructured":"Yap DYH, Tang CSO, Ma MKM, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. 2012;27:3248\u201354.","journal-title":"Nephrol Dial Transplant"},{"key":"735_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","volume":"55","author":"JG Hanly","year":"2016","unstructured":"Hanly JG, O\u2019Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016;55:252\u201362.","journal-title":"Rheumatology (Oxford)"},{"key":"735_CR11","volume":"13","author":"S Sarwar","year":"2021","unstructured":"Sarwar S, Mohamed AS, Rogers S, et al. Neuropsychiatric systemic lupus erythematosus: a 2021 update on diagnosis, management, and current challenges. Cureus. 2021;13:e17969.","journal-title":"Cureus"},{"key":"735_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41584-018-0156-8","volume":"15","author":"N Schwartz","year":"2019","unstructured":"Schwartz N, Stock AD, Putterman C. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol. 2019;15:137\u201352.","journal-title":"Nat Rev Rheumatol"},{"key":"735_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fneph.2022.984613","volume":"2","author":"G Moroni","year":"2022","unstructured":"Moroni G, Calatroni M, Ponticelli C. Severe lupus nephritis in the present days. Front Nephrol. 2022;2:984613.","journal-title":"Front Nephrol"},{"key":"735_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fmed.2018.00138","volume":"5","author":"JF Vivaldo","year":"2018","unstructured":"Vivaldo JF, de Amorim JC, Julio PR, de Oliveira RJ, Appenzeller S. Definition of NPSLE: does the ACR nomenclature still hold? Front Med (Lausanne). 2018;5:138.","journal-title":"Front Med (Lausanne)"},{"key":"735_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79:713\u201323.","journal-title":"Ann Rheum Dis"},{"key":"735_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83:15\u201329.","journal-title":"Ann Rheum Dis"},{"key":"735_CR17","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","volume":"73","author":"RF van Vollenhoven","year":"2014","unstructured":"van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73:958\u201367.","journal-title":"Ann Rheum Dis"},{"key":"735_CR18","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.3390\/jcm12093348","volume":"12","author":"D Zucchi","year":"2023","unstructured":"Zucchi D, Cardelli C, Elefante E, Tani C, Mosca M. Treat-to-target in systemic lupus erythematosus: reality or pipe dream. J Clin Med. 2023;12:3348.","journal-title":"J Clin Med"},{"key":"735_CR19","unstructured":"European Medicines Agency. Benlysta (bemilumab). Summary of product characteristics. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/benlysta-epar-product-information_en.pdf. Accessed 6 Jul 2023."},{"key":"735_CR20","unstructured":"European Medicines Agency. Saphnelo (anifrolumab). Summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/saphnelo-epar-product-information_en.pdf. Accessed 6 Jul 2023."},{"issue":"5","key":"735_CR21","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/rheumatology\/keaa403","volume":"59","author":"G Ruiz-Irastorza","year":"2020","unstructured":"Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020;59(5):v69-81.","journal-title":"Rheumatology (Oxford)"},{"key":"735_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000513","volume":"8","author":"S Dyball","year":"2021","unstructured":"Dyball S, Collinson S, Sutton E, McCarthy EM, Bruce IN, Parker B. Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR). Lupus Sci Med. 2021;8: e000513.","journal-title":"Lupus Sci Med"},{"key":"735_CR23","unstructured":"National Institute for Health and Care Excellence. NICE real-world evidence framework. 2022. https:\/\/www.nice.org.uk\/corporate\/ecd9\/resources\/nice-realworld-evidence-framework-pdf-1124020816837. Accessed 23 Feb 2024."},{"issue":"1","key":"735_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00393-022-01302-5","volume":"83","author":"K Albrecht","year":"2024","unstructured":"Albrecht K, Binder S, Minden K, et al. Systematic review to estimate the prevalence of inflammatory rheumatic diseases in Germany. Z Rheumatol. 2024;83(1):20\u201330.","journal-title":"Z Rheumatol"},{"key":"735_CR25","unstructured":"Thiele K, Albrecht K, Alexander T, et al. Yearly results of the German National Database of the Cooperative Collaborative Arthritis Centers. 2023. https:\/\/refubium.fu-berlin.de\/bitstream\/handle\/fub188\/39587\/2023_Thiele_etal.pdf?sequence=3&isAllowed=y. Accessed 12 Sep 2023."},{"key":"735_CR26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00103-020-03110-1","volume":"63","author":"CO Schmidt","year":"2020","unstructured":"Schmidt CO, G\u00fcnther K-P, Goronzy J, et al. H\u00e4ufigkeiten muskuloskelettaler Symptome und Erkrankungen in der bev\u00f6lkerungsbezogenen NAKO Gesundheitsstudie [Frequencies of musculoskeletal symptoms and disorders in the population-based German National Cohort (GNC)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020;63:415\u201325.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"735_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40744-021-00277-0","volume":"8","author":"A Schwarting","year":"2021","unstructured":"Schwarting A, Friedel H, Garal-Pantaler E, et al. The burden of systemic lupus erythematosus in Germany: incidence, prevalence, and healthcare resource utilization. Rheumatol Ther. 2021;8:375\u201393.","journal-title":"Rheumatol Ther"},{"key":"735_CR28","unstructured":"Thiele K, Albrecht K, Alexander T, et al. Core Documentation of Regional Cooperative Rheumatism Centers - Care Trends 2024. 2024. https:\/\/refubium.fu-berlin.de\/bitstream\/handle\/fub188\/42257\/Kerndokumentation_Versorgungstrends_2024.pdf. Accessed 19 Apr 2024."},{"key":"735_CR29","doi-asserted-by":"publisher","first-page":"adv00309","DOI":"10.2340\/00015555-3655","volume":"100","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder S, Ketz M, Kossack N, et al. Epidemiology of prurigo nodularis compared with psoriasis in Germany: a claims database analysis. Acta Derm Venereol. 2020;100:adv00309.","journal-title":"Acta Derm Venereol"},{"key":"735_CR30","unstructured":"Federal Institute for Drugs and Medical Devices. ICD-10-GM International Statistical Classification of Diseases, German modification. 2024. https:\/\/www.bfarm.de\/EN\/Code-systems\/Classifications\/ICD\/ICD-10-GM\/_node.html. Accessed 19 Apr 2024."},{"key":"735_CR31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"735_CR32","unstructured":"Statistisches Bundesamt (Destatis). Online database query for \u201aBev\u00f6lkerung: Deutschland, Stichtag 31.12.2019. 2024. Accessed 9 Oct 2024."},{"key":"735_CR33","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","volume":"56","author":"F Rees","year":"2017","unstructured":"Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017;56:1945\u201361.","journal-title":"Rheumatology (Oxford)"},{"key":"735_CR34","doi-asserted-by":"publisher","first-page":"5631","DOI":"10.1038\/s41598-021-84957-5","volume":"11","author":"PY Leong","year":"2021","unstructured":"Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. Sci Rep. 2021;11:5631.","journal-title":"Sci Rep"},{"key":"735_CR35","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1053\/berh.2002.0259","volume":"16","author":"M Petri","year":"2002","unstructured":"Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2002;16:847\u201358.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"735_CR36","doi-asserted-by":"publisher","first-page":"e000181","DOI":"10.1136\/lupus-2016-000181","volume":"3","author":"R Brinks","year":"2016","unstructured":"Brinks R, Hoyer A, Weber S, et al. Age-specific and sex-specific incidence of systemic lupus erythematosus: an estimate from cross-sectional claims data of 2.3\u00a0million people in the German statutory health insurance 2002. Lupus Sci Med. 2016;3:e000181.","journal-title":"Lupus Sci Med"},{"key":"735_CR37","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1053\/j.gastro.2019.01.002","volume":"156","author":"S Coward","year":"2019","unstructured":"Coward S, Clement F, Benchimol EI, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology. 2019;156:1345-53.e4.","journal-title":"Gastroenterology"},{"key":"735_CR38","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/ibd\/izab096","volume":"28","author":"JN Pe\u00f1a-S\u00e1nchez","year":"2022","unstructured":"Pe\u00f1a-S\u00e1nchez JN, Amankwah Osei J, Marques Santos JD, et al. Increasing prevalence and stable incidence rates of inflammatory bowel disease among first nations: population-based evidence from a western Canadian province. Inflamm Bowel Dis. 2022;28:514\u201322.","journal-title":"Inflamm Bowel Dis"},{"key":"735_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002949","volume":"9","author":"J Rathmann","year":"2023","unstructured":"Rathmann J, Segelmark M, Englund M, Mohammad AJ. Stable incidence but increase in prevalence of ANCA-associated vasculitis in southern Sweden: a 23-year study. RMD Open. 2023;9:e002949.","journal-title":"RMD Open"},{"key":"735_CR40","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/rheumatology\/keac218","volume":"62","author":"W Luo","year":"2022","unstructured":"Luo W, Farinha F, Isenberg DA, Rahman A. Survival analysis of mortality and development of lupus nephritis in patients with systemic lupus erythematosus up to 40\u00a0years of follow-up. Rheumatology (Oxford). 2022;62:200\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"735_CR41","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3389\/fmed.2020.00552","volume":"7","author":"CC Mok","year":"2020","unstructured":"Mok CC, Ho LY, Chan KL, Tse SM, To CH. Trend of survival of a cohort of Chinese patients with systemic lupus erythematosus over 25\u00a0years. Front Med (Lausanne). 2020;7:552.","journal-title":"Front Med (Lausanne)"},{"key":"735_CR42","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1093\/rheumatology\/keac685","volume":"62","author":"M Zen","year":"2023","unstructured":"Zen M, Salmaso L, Barbiellini Amidei C, et al. Systemic lupus erythematosus incidence and prevalence in a large population-based study in northeastern Italy. Rheumatology (Oxford). 2023;62:2773\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"735_CR43","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/annrheumdis-2014-206334","volume":"75","author":"F Rees","year":"2016","unstructured":"Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999\u20132012. Ann Rheum Dis. 2016;75:136\u201341.","journal-title":"Ann Rheum Dis"},{"key":"735_CR44","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.autrev.2014.08.034","volume":"13","author":"L Arnaud","year":"2014","unstructured":"Arnaud L, Fagot J-P, Mathian A, Paita M, Fagot-Campagna A, Amoura Z. Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. Autoimmun Rev. 2014;13:1082\u20139.","journal-title":"Autoimmun Rev"},{"key":"735_CR45","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/S2665-9913(22)00288-0","volume":"4","author":"H Haukeland","year":"2022","unstructured":"Haukeland H, Reppe Moe S, Brunborg C, et al. Gender differences in the incidence of systemic lupus erythematosus in Norway: a population-based cohort study. Lancet Rheumatol. 2022;4:S9.","journal-title":"Lancet Rheumatol"},{"key":"735_CR46","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00296-018-4091-4","volume":"38","author":"F Fatoye","year":"2018","unstructured":"Fatoye F, Gebrye T, Svenson LW. Real-world incidence and prevalence of systemic lupus erythematosus in Alberta. Canada Rheumatol Int. 2018;38:1721\u20136.","journal-title":"Canada Rheumatol Int"},{"key":"735_CR47","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1177\/09612033241242692","volume":"33","author":"S Emamikia","year":"2024","unstructured":"Emamikia S, Gomez A, \u00c5dahl T, et al. Factors associated with non-adherence to medications in systemic lupus erythematosus: results from a Swedish survey. Lupus. 2024;33:615\u201328.","journal-title":"Lupus"},{"key":"735_CR48","doi-asserted-by":"publisher","first-page":"v29","DOI":"10.1093\/rheumatology\/keaa382","volume":"59","author":"L Arnaud","year":"2020","unstructured":"Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology. 2020;59:v29\u201338.","journal-title":"Rheumatology"},{"key":"735_CR49","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1586\/eci.10.98","volume":"7","author":"M McMahon","year":"2011","unstructured":"McMahon M, Hahn BH, Skaggs BJ. Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol. 2011;7:227\u201341.","journal-title":"Expert Rev Clin Immunol"},{"key":"735_CR50","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/rheumatology\/ker410","volume":"51","author":"G Ruiz-Irastorza","year":"2012","unstructured":"Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012;51:1145\u201353.","journal-title":"Rheumatology (Oxford)"},{"key":"735_CR51","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/rheumatology\/keae227","volume":"63","author":"M Mosca","year":"2024","unstructured":"Mosca M, Bruce IN, Andersen J, Ugarte-Gil MF, Arnaud L. Challenges and opportunities in access to care for systemic lupus erythematosus patients across Europe and worldwide. Rheumatology. 2024;63:1772\u20138.","journal-title":"Rheumatology"},{"key":"735_CR52","unstructured":"European Commission. European Reference Networks. https:\/\/health.ec.europa.eu\/rare-diseases-and-european-reference-networks\/european-reference-networks_en. Accessed 2 Oct 2024."},{"key":"735_CR53","unstructured":"GlaxoSmithKline. GSK receives European marketing authorisation for self-injectable formulation of Benlysta for the treatment of systemic lupus erythematosus. 2017. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-receives-european-marketing-authorisation-for-self-injectable-formulation-of-benlysta-for-the-treatment-of-systemic-lupus-erythematosus\/. Accessed 23 Feb 2024."}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00735-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00735-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00735-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T20:05:12Z","timestamp":1742328312000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00735-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["735"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00735-5","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"2 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tobias Alexander has received consulting fees from Amgen; honoraria from AbbVie, AstraZeneca, GSK, Neovii and Pfizer; support for attending meetings, and\/or travel support, from AbbVie, Neovii and Pfizer; and study support from Janssen-Cilag. Philipp Sewerin has received consulting fees from Amgen; honoraria and support for attending meetings, and\/or travel support, from AbbVie, Alfasigma S.p.A., Amgen, Axiom Health, Biogen, Bristol-Myers Squibb, Celgene, Chugai, Gilead Sciences, Hexal, Janssen-Cilag, Johnson & Johnson, Lilly, mediri GmbH, Novartis Pharma, Onkowissen GmbH, Pfizer, Roche, Sanofi-Genzyme, Swedish Orphan Biovitrum and UCB Pharma. Anja Strangfeld has received honoraria from AbbVie, Galapagos, Lilly, Janssen, Pfizer and Takeda; is Chair of the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) Data Monitoring Committee (voluntary role); and is on the Data Monitoring Committee Board of the Lupus Best Study (voluntary role). Marcus Schulte and Eva Schrom are employees of, and hold stocks in, Amgen. Julia Borchert and Tarcyane Barata Garcia are employees of WIG2 GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study used anonymised secondary data (i.e. healthcare insurance claims data); hence, ethics approval and consent to participate were not applicable. Patient consent for publication was also not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}